Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.71 USD
-0.05 (-2.84%)
Updated Aug 27, 2024 04:00 PM ET
After-Market: $1.70 -0.01 (-0.58%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Cash flow Statements
Fiscal Year End for Esperion Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -209.25 | -233.66 | -269.11 | -143.55 | -97.17 |
Depreciation/Amortization & Depletion | 1.45 | 2.40 | 2.25 | 2.19 | 0.12 |
Net Change from Assets/Liabilities | 13.68 | -3.37 | -52.51 | -4.26 | -7.30 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 58.64 | 59.81 | 55.57 | 60.45 | 34.00 |
Net Cash From Operating Activities | -135.49 | -174.83 | -263.81 | -85.18 | -70.34 |
Property & Equipment | 0.00 | 0.00 | 0.00 | -0.87 | -0.95 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 42.50 | 8.10 | -50.48 | 34.73 | 65.18 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | -12.50 | 0.00 |
Net Cash from Investing Activities | 42.50 | 8.10 | -50.48 | 21.36 | 64.23 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 65.97 | 90.85 | 222.45 | -48.37 | 11.77 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 280.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | -46.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -15.51 | -58.24 | 45.77 | 16.10 | 124.42 |
Net Cash from Financing Activities | 50.46 | 32.61 | 268.22 | 201.73 | 136.20 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -42.53 | -134.12 | -46.07 | 137.90 | 130.09 |
Cash at Beginning of Period | 124.78 | 258.89 | 304.96 | 167.06 | 36.97 |
Cash at End of Period | 82.25 | 124.78 | 258.89 | 304.96 | 167.06 |
Diluted Net EPS | -2.03 | -3.52 | -9.31 | -5.23 | -3.59 |
Fiscal Year End for Esperion Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -0.90 | 61.02 | -209.25 | -152.90 | -111.65 |
Depreciation/Amortization & Depletion | 0.89 | 0.44 | 1.45 | 1.01 | 0.56 |
Net Change from Assets/Liabilities | -26.80 | -21.80 | 13.68 | 9.72 | 3.14 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 73.44 | 14.17 | 58.64 | 43.74 | 28.85 |
Net Cash From Operating Activities | 46.62 | 53.83 | -135.49 | -98.43 | -79.11 |
Property & Equipment | -0.15 | -0.07 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 42.50 | 42.50 | 42.50 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.15 | -0.07 | 42.50 | 42.50 | 42.50 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 105.51 | 96.44 | 65.97 | 56.90 | 56.92 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -44.93 | -5.83 | -15.51 | -10.91 | -6.62 |
Net Cash from Financing Activities | 60.58 | 90.61 | 50.46 | 45.99 | 50.30 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 107.06 | 144.36 | -42.53 | -9.94 | 13.70 |
Cash at Beginning of Period | 82.25 | 82.25 | 124.78 | 124.78 | 124.78 |
Cash at End of Period | 189.30 | 226.61 | 82.25 | 114.83 | 138.47 |
Diluted Net EPS | -0.33 | 0.34 | -0.41 | -0.37 | -0.46 |